Advanced in Small Cell Lung Cancer (SCLC)

Muhammad Alamgeer

Wellington Road, 
Clayton, VIC, AU 
Advanced in Small Cell Lung Cancer (SCLC)
Wellington Road, 
Clayton, VIC, AU 
OverviewLocationsClinical Research

Overview

Muhammad Alamgeer practices in Clayton, Australia. Mr. Alamgeer is rated as an Advanced expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Oral Herpes, Lung Cancer, and Breast Cancer.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Small Cell Lung Cancer (SCLC).

Gender
Male

Locations

Wellington Road, Clayton, VIC 3168, Australia
Other Locations
27-31 Wright Street, Clayton, VIC 3168, Australia
823-865 Centre Road, Bentleigh, VIC 3165, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
Enrollment Status: Terminated
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

23 Total Publications

FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study).
FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study).
Journal: British journal of anaesthesia
Published: November 20, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Alamgeer's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile